<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04532801</url>
  </required_header>
  <id_info>
    <org_study_id>267337</org_study_id>
    <nct_id>NCT04532801</nct_id>
  </id_info>
  <brief_title>Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Physiologic Mixed Meal Tolerance</brief_title>
  <official_title>Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Physiologic Mixed Meal Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stephanie B. Seminara, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study utilizes infusions of kisspeptin in healthy women to isolate the impact of&#xD;
      kisspeptin on beta-cell responsivity assessed by the mixed meal tolerance test.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assignment: each study subject serves as their own control, and will come in timed to their&#xD;
      cycle. The order in which they undergo the kisspeptin or placebo arms is randomized and&#xD;
      separated by greater than two weeks to minimize variability and study-specific effects.&#xD;
&#xD;
      Delivery of Interventions:&#xD;
&#xD;
      Prior to each visit, study subjects will be asked to:&#xD;
&#xD;
        -  eat at least 150 gm carbohydrates per day&#xD;
&#xD;
        -  refrain from strenuous exercise&#xD;
&#xD;
      On the day of the visit, study subjects will:&#xD;
&#xD;
        -  eat a standardized meal prepared by the metabolic kitchen in the clinical research&#xD;
           center&#xD;
&#xD;
        -  be observed overnight to ensure a 12-hour fast&#xD;
&#xD;
        -  have an IV placed, for a 16 hour kisspeptin or placebo infusion&#xD;
&#xD;
        -  after the 12 hour fast, starting at 8 am in the morning will undergo a mixed meal&#xD;
           tolerance test&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>physiologic studies</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Beta-cell responsivity index</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Average beta-cell responsivity index derived from mixed meal tolerance data comparing placebo and kisspeptin arms</description>
  </primary_outcome>
  <other_outcome>
    <measure>Fasting insulin level</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Average fasting insulin level comparing placebo and kisspeptin arms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Insulin</condition>
  <condition>Glucose</condition>
  <condition>Healthy Volunteers</condition>
  <condition>Women</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>kisspeptin-10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>kisspeptin infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kisspeptin-10</intervention_name>
    <description>kisspeptin-10 IV infusion</description>
    <arm_group_label>kisspeptin-10</arm_group_label>
    <other_name>kisspeptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mixed meal tolerance test</intervention_name>
    <description>mixed meal tolerance test</description>
    <arm_group_label>kisspeptin-10</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        HISTORY&#xD;
&#xD;
          -  no personal history of chronic disease, except well controlled thyroid disease&#xD;
&#xD;
          -  no history of diabetes in a first degree relative, including gestational diabetes&#xD;
&#xD;
          -  no family or personal history of hyperlipidemia&#xD;
&#xD;
          -  normal timing of menarche (age 10-14)&#xD;
&#xD;
          -  normal menstrual cycles (q25-35 days)&#xD;
&#xD;
          -  no use of contraceptive pills, patches or vaginal rings within last 4 weeks&#xD;
&#xD;
          -  nulliparous (no history of a pregnancy)&#xD;
&#xD;
          -  no active illicit drug use&#xD;
&#xD;
          -  no history of a medication reaction requiring emergency medical care&#xD;
&#xD;
          -  no difficulty with blood draws&#xD;
&#xD;
          -  stable weight for previous three months&#xD;
&#xD;
          -  available for all parts of the study&#xD;
&#xD;
        PHYSICAL&#xD;
&#xD;
          -  body mass index (18.5-25)&#xD;
&#xD;
          -  systolic BP &lt; 120mm Hg, diastolic &lt; 80 mm Hg&#xD;
&#xD;
          -  normal waist circumference (less than 32 inches)&#xD;
&#xD;
        LABORATORY STUDIES: (per Massachusetts General Hospital reference ranges)&#xD;
&#xD;
          -  fasting LDL cholesterol less than 130 mg/dL&#xD;
&#xD;
          -  fasting triglycerides less than 150 mg/dL&#xD;
&#xD;
          -  normal hemoglobin&#xD;
&#xD;
          -  hemoglobin A1C &lt; 5.7%&#xD;
&#xD;
          -  blood urea nitrogen, creatinine not elevated&#xD;
&#xD;
          -  AST, ALT not elevated&#xD;
&#xD;
          -  negative serum pregnancy test&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Lippincott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret Lippincott, MD</last_name>
    <phone>617-726-8434</phone>
    <email>mlippincott@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>General Research Email</last_name>
    <email>mghkisspeptinresearch@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Lippincott, MD</last_name>
      <phone>617-726-8434</phone>
      <email>mlippincott@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 23, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Stephanie B. Seminara, MD</investigator_full_name>
    <investigator_title>Chief, Reproductive Endocrine Unit; Professor of Medicine, Harvard Medical School; Director, Harvard Reproductive Endocrine Sciences Center</investigator_title>
  </responsible_party>
  <keyword>kisspeptin</keyword>
  <keyword>follicular phase</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

